{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T23:22:46Z","timestamp":1778714566733,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1038\/s41401-024-01288-7","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T11:02:13Z","timestamp":1715684533000},"page":"1926-1936","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Iguratimod suppresses plasma cell differentiation and ameliorates experimental Sj\u00f6gren\u2019s syndrome in mice by promoting TEC kinase degradation"],"prefix":"10.1038","volume":"45","author":[{"given":"Ya-qi","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-xuan","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun-wei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-xi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"key":"1288_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.47","volume":"2","author":"P Brito-Zer\u00f3n","year":"2016","unstructured":"Brito-Zer\u00f3n P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, et al. Sj\u00f6gren syndrome. Nat Rev Dis Prim. 2016;2:16047.","journal-title":"Nat Rev Dis Prim"},{"key":"1288_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.autrev.2009.07.002","volume":"9","author":"L Kov\u00e1cs","year":"2010","unstructured":"Kov\u00e1cs L, Szodoray P, Kiss E. Secondary tumours in Sj\u00f6gren\u2019s syndrome. Autoimmun Rev. 2010;9:203\u20136.","journal-title":"Autoimmun Rev"},{"key":"1288_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102335","volume":"104","author":"S Katsiougiannis","year":"2019","unstructured":"Katsiougiannis S, Tenta R, Skopouli FN. Autoimmune epithelitis (Sj\u00f6gren\u2019s syndrome); the impact of metabolic status of glandular epithelial cells on auto-immunogenicity. J Autoimmun. 2019;104:102335.","journal-title":"J Autoimmun"},{"key":"1288_CR4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.autrev.2012.10.006","volume":"12","author":"YH Yao","year":"2013","unstructured":"Yao YH, Liu Z, Jallal B, Shen N, R\u00f6nnblom L. Type I interferons in Sj\u00f6gren\u2019s syndrome. Autoimmun Rev. 2013;12:558\u201366.","journal-title":"Autoimmun Rev"},{"key":"1288_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1172\/JCI107536","volume":"53","author":"N Talal","year":"1974","unstructured":"Talal N, Sylvester RA, Daniels TE, Greenspan JS, Williams RC Jr. T and B lymphocytes in peripheral blood and tissue lesions in Sj\u00f6gren\u2019s syndrome. J Clin Invest. 1974;53:180\u20139.","journal-title":"J Clin Invest"},{"key":"1288_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaut.2012.05.014","volume":"39","author":"D Cornec","year":"2012","unstructured":"Cornec D, Devauchelle-Pensec V, Tob\u00f3n GJ, Pers JO, Jousse-Joulin S, Saraux A. B cells in Sj\u00f6gren\u2019s syndrome: from pathophysiology to diagnosis and treatment. J Autoimmun. 2012;39:161\u20137.","journal-title":"J Autoimmun"},{"key":"1288_CR7","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1002\/art.39315","volume":"67","author":"G Nocturne","year":"2015","unstructured":"Nocturne G, Seror R, Fogel O, Belkhir R, Boudaoud S, Saraux A, et al. CXCL13 and CCL11 serum levels and lymphoma and disease activity in Primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol. 2015;67:3226\u201333.","journal-title":"Arthritis Rheumatol"},{"key":"1288_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jaut.2010.07.004","volume":"35","author":"NS Zuckerman","year":"2010","unstructured":"Zuckerman NS, Hazanov H, Barak M, Edelman H, Hess S, Shcolnik H, et al. Somatic hypermutation and antigen-driven selection of B cells are altered in autoimmune diseases. J Autoimmun. 2010;35:325\u201335.","journal-title":"J Autoimmun"},{"key":"1288_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.coi.2015.01.018","volume":"33","author":"SW Jackson","year":"2015","unstructured":"Jackson SW, Kolhatkar NS, Rawlings DJ. B cells take the front seat: dysregulated B cell signals orchestrate loss of tolerance and autoantibody production. Curr Opin Immunol. 2015;33:70\u201377.","journal-title":"Curr Opin Immunol"},{"key":"1288_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1172\/JCI0214121","volume":"109","author":"J Groom","year":"2002","unstructured":"Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, et al. Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sj\u00f6gren\u2019s syndrome. J Clin Invest. 2002;109:59\u201368.","journal-title":"J Clin Invest"},{"key":"1288_CR11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1136\/ard.62.2.168","volume":"62","author":"X Mariette","year":"2003","unstructured":"Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis. 2003;62:168\u201371.","journal-title":"Ann Rheum Dis"},{"key":"1288_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10238-020-00637-0","volume":"20","author":"FJ Carrillo-Ballesteros","year":"2020","unstructured":"Carrillo-Ballesteros FJ, Palafox-Sanchez CA, Franco-Topete RA, Munoz-Valle JF, Orozco-Barocio G, Martinez-Bonilla GE, et al. Expression of BAFF and BAFF receptors in primary Sj\u00f6gren\u2019s syndrome patients with ectopic germinal center-like structures. Clin Exp Med. 2020;20:615\u201326.","journal-title":"Clin Exp Med"},{"key":"1288_CR13","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/rheumatology\/kes180","volume":"52","author":"L Quartuccio","year":"2013","unstructured":"Quartuccio L, Salvin S, Fabris M, Maset M, Pontarini E, Isola M, et al. BLyS upregulation in Sj\u00f6gren\u2019s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxf). 2013;52:276\u201381.","journal-title":"Rheumatology (Oxf)"},{"key":"1288_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.55563\/clinexprheumatol\/fp741f","volume":"39","author":"J Loureiro-Amigo","year":"2021","unstructured":"Loureiro-Amigo J, Franco-Jarava C, Perurena-Prieto J, Palacio C, Martinez-Valle F, Solans-Laque R. Serum CXCL13, BAFF, IL-21 and IL-22 levels are related to disease activity and lymphocyte profile in primary Sj\u00f6gren\u2019s syndrome. Clin Exp Rheumatol. 2021;39:131\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"1288_CR15","first-page":"e584","volume":"9","author":"JJ Nair","year":"2017","unstructured":"Nair JJ, Singh TP. Sj\u00f6gren\u2019s syndrome: Review of the aetiology, pathophysiology & potential therapeutic interventions. J Clin Exp Dent. 2017;9:e584\u2013e9.","journal-title":"J Clin Exp Dent"},{"key":"1288_CR16","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/nrrheum.2016.100","volume":"12","author":"A Saraux","year":"2016","unstructured":"Saraux A, Pers JO, Devauchelle-Pensec V. Treatment of primary Sj\u00f6gren syndrome. Nat Rev Rheumatol. 2016;12:456\u201371.","journal-title":"Nat Rev Rheumatol"},{"key":"1288_CR17","doi-asserted-by":"publisher","first-page":"e001064","DOI":"10.1136\/rmdopen-2019-001064","volume":"5","author":"P Brito-Zeron","year":"2019","unstructured":"Brito-Zeron P, Retamozo S, Kostov B, Baldini C, Bootsma H, De Vita S, et al. Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome. RMD Open. 2019;5:e001064.","journal-title":"RMD Open"},{"key":"1288_CR18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.reuma.2020.03.003","volume":"17","author":"N Alvarez-Rivas","year":"2021","unstructured":"Alvarez-Rivas N, Sang-Park H, Diaz Del Campo P, Fernandez-Castro M, Corominas H, Andreu JL, et al. Efficacy of belimumab in Primary Sj\u00f6gren\u2019s syndrome: a systematic review. Reumatol Clin (Engl Ed). 2021;17:170\u20134.","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"1288_CR19","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.163030","volume":"7","author":"X Mariette","year":"2022","unstructured":"Mariette X, Barone F, Baldini C, Bootsma H, Clark KL, De Vita S, et al. A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren\u2019s syndrome. JCI Insight. 2022;7:e163030.","journal-title":"JCI Insight"},{"key":"1288_CR20","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40259-021-00505-7","volume":"35","author":"B Wang","year":"2021","unstructured":"Wang B, Chen SJ, Li Y, Xuan JX, Liu Y, Shi GX. Targeted therapy for Primary Sj\u00f6gren\u2019s syndrome: where are we now? BioDrugs. 2021;35:593\u2013610.","journal-title":"BioDrugs"},{"key":"1288_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","volume":"399","author":"SJ Bowman","year":"2022","unstructured":"Bowman SJ, Fox R, D\u00f6rner T, Mariette X, Papas A, Grader-Beck T, et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet. 2022;399:161\u201371.","journal-title":"Lancet"},{"key":"1288_CR22","first-page":"2398","volume":"40","author":"A Kaklamanos","year":"2022","unstructured":"Kaklamanos A, Goules AV, Tzioufas AG. Experimental models of Sj\u00f6gren\u2019s syndrome: differences and similarities with human disease. Clin Exp Rheumatol. 2022;40:2398\u2013412.","journal-title":"Clin Exp Rheumatol"},{"key":"1288_CR23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1586\/1744666X.2015.1027151","volume":"11","author":"K Tanaka","year":"2015","unstructured":"Tanaka K, Yamaguchi T, Hara M. Iguratimod for the treatment of rheumatoid arthritis in Japan. Expert Rev Clin Immunol. 2015;11:565\u201373.","journal-title":"Expert Rev Clin Immunol"},{"key":"1288_CR24","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.4049\/jimmunol.1300832","volume":"191","author":"Q Luo","year":"2013","unstructured":"Luo Q, Sun Y, Liu W, Qian C, Jin B, Tao FF, et al. A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. J Immunol. 2013;191:4969\u201378.","journal-title":"J Immunol"},{"key":"1288_CR25","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.immuni.2023.06.012","volume":"56","author":"Q Luo","year":"2023","unstructured":"Luo Q, Liu YJ, Shi K, Shen XC, Yang YQ, Liang XJ, et al. An autonomous activation of interleukin-17 receptor signaling sustains inflammation and promotes disease progression. Immunity. 2023;56:2006\u201320.","journal-title":"Immunity"},{"key":"1288_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113460","volume":"153","author":"WP Liu","year":"2022","unstructured":"Liu WP, Han X, Li Q, Sun LQ, Wang JB. Iguratimod ameliorates bleomycin-induced pulmonary fibrosis by inhibiting the EMT process and NLRP3 inflammasome activation. Biomed Pharmacother. 2022;153:113460.","journal-title":"Biomed Pharmacother"},{"key":"1288_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.746317","volume":"9","author":"M Zhang","year":"2021","unstructured":"Zhang M, Lei YS, Meng XW, Liu HY, Li LG, Zhang J, et al. Iguratimod alleviates myocardial ischemia\/reperfusion injury through inhibiting inflammatory response induced by cardiac fibroblast pyroptosis via COX2\/NLRP3 signaling pathway. Front Cell Dev Biol. 2021;9:746317.","journal-title":"Front Cell Dev Biol"},{"key":"1288_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20390-5","volume":"8","author":"GR Li","year":"2018","unstructured":"Li GR, Yamasaki R, Fang M, Masaki K, Ochi H, Matsushita T, et al. Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages\/microglia through an NF-kappaB pathway. Sci Rep. 2018;8:1933.","journal-title":"Sci Rep"},{"key":"1288_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107563","volume":"96","author":"Y Xia","year":"2021","unstructured":"Xia Y, Fang X, Dai XJ, Li MY, Jin L, Tao JH, et al. Iguratimod ameliorates nephritis by modulating the Th17\/Treg paradigm in pristane-induced lupus. Int Immunopharmacol. 2021;96:107563.","journal-title":"Int Immunopharmacol"},{"key":"1288_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.molimm.2017.10.008","volume":"93","author":"XP Jiang","year":"2018","unstructured":"Jiang XP, Huang XL, Yang ZP, Wang SC, Xie W, Miao L, et al. Iguratimod ameliorates inflammatory responses by modulating the Th17\/Treg paradigm in dextran sulphate sodium-induced murine colitis. Mol Immunol. 2018;93:9\u201319.","journal-title":"Mol Immunol"},{"key":"1288_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.924730","volume":"13","author":"LT Zeng","year":"2022","unstructured":"Zeng LT, He Q, Yang KL, Hao WS, Yu GP, Chen H. A systematic review and meta-analysis of 19 randomized controlled trials of iguratimod combined with other therapies for Sj\u00f6gren\u2019s syndrome. Front Immunol. 2022;13:924730.","journal-title":"Front Immunol"},{"key":"1288_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.621208","volume":"12","author":"JC Pu","year":"2021","unstructured":"Pu JC, Wang X, Riaz F, Zhang TYZ, Gao RL, Pan SN, et al. Effectiveness and safety of iguratimod in treating primary Sj\u00f6gren\u2019s syndrome: a systematic review and meta-analysis. Front Pharmacol. 2021;12:621208.","journal-title":"Front Pharmacol"},{"key":"1288_CR33","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/cmi.2017.8","volume":"14","author":"F Xiao","year":"2017","unstructured":"Xiao F, Lin X, Tian J, Wang XH, Chen Q, Rui K, et al. Proteasome inhibition suppresses Th17 cell generation and ameliorates autoimmune development in experimental Sj\u00f6gren\u2019s syndrome. Cell Mol Immunol. 2017;14:924\u201334.","journal-title":"Cell Mol Immunol"},{"key":"1288_CR34","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/BF00918804","volume":"11","author":"RH Scofield","year":"1991","unstructured":"Scofield RH, Dickey WD, Jackson KW, James JA, Harley JB. A common autoepitope near the carboxyl terminus of the 60-kD Ro ribonucleoprotein: sequence similarity with a viral protein. J Clin Immunol. 1991;11:378\u201388.","journal-title":"J Clin Immunol"},{"key":"1288_CR35","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41423-020-00587-3","volume":"18","author":"K Rui","year":"2021","unstructured":"Rui K, Hong Y, Zhu QG, Shi XF, Xiao F, Fu HL, et al. Olfactory ecto-mesenchymal stem cell-derived exosomes ameliorate murine Sj\u00f6gren\u2019s syndrome by modulating the function of myeloid-derived suppressor cells. Cell Mol Immunol. 2021;18:440\u201351.","journal-title":"Cell Mol Immunol"},{"key":"1288_CR36","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/978-1-0716-1736-6_18","volume":"2380","author":"S Yu","year":"2022","unstructured":"Yu S, Wu ML, Feng Y, Shen JG, Lu LW, Lin X. Detection of T follicular helper cells and T follicular regulatory cells in experimental Sj\u00f6gren\u2019s syndrome. Methods Mol Biol. 2022;2380:211\u201324.","journal-title":"Methods Mol Biol"},{"key":"1288_CR37","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00011-022-01660-5","volume":"71","author":"J Tian","year":"2022","unstructured":"Tian J, Zhang BB, Yuan QF, Sun XQ, Peng N, Zhu B, et al. GITRL impairs the immunosuppressive function of MDSCs via PTEN-mediated signaling pathway in experimental Sj\u00f6gren syndrome. Inflamm Res. 2022;71:1577\u201388.","journal-title":"Inflamm Res"},{"key":"1288_CR38","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/s41423-022-00943-5","volume":"19","author":"YX Wei","year":"2022","unstructured":"Wei YX, Peng N, Deng C, Zhao F, Tian J, Tang Y, et al. Aryl hydrocarbon receptor activation drives polymorphonuclear myeloid-derived suppressor cell response and efficiently attenuates experimental Sj\u00f6gren\u2019s syndrome. Cell Mol Immunol. 2022;19:1361\u201372.","journal-title":"Cell Mol Immunol"},{"key":"1288_CR39","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41584-021-00605-2","volume":"17","author":"GM Verstappen","year":"2021","unstructured":"Verstappen GM, Pringle S, Bootsma H, Kroese FGM. Epithelial-immune cell interplay in primary Sj\u00f6gren syndrome salivary gland pathogenesis. Nat Rev Rheumatol. 2021;17:333\u201348.","journal-title":"Nat Rev Rheumatol"},{"key":"1288_CR40","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1128\/MCB.24.6.2455-2466.2004","volume":"24","author":"MG Tomlinson","year":"2004","unstructured":"Tomlinson MG, Kane LP, Su J, Kadlecek TA, Mollenauer MN, Weiss A. Expression and function of Tec, Itk, and Btk in lymphocytes: evidence for a unique role for Tec. Mol Cell Biol. 2004;24:2455\u201366.","journal-title":"Mol Cell Biol"},{"key":"1288_CR41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12876-018-0858-z","volume":"18","author":"XL Li","year":"2018","unstructured":"Li XL, Liu XC, Song YL, Hong RT, Shi H. Suspected drug-induced liver injury associated with iguratimod: a case report and review of the literature. BMC Gastroenterol. 2018;18:130.","journal-title":"BMC Gastroenterol"},{"key":"1288_CR42","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.","journal-title":"Front Immunol"},{"key":"1288_CR43","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13075-019-1874-2","volume":"21","author":"Y Ye","year":"2019","unstructured":"Ye Y, Liu M, Tang LH, Du F, Liu YH, Hao P, et al. Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC\/EGR1 axis. Arthritis Res Ther. 2019;21:92.","journal-title":"Arthritis Res Ther"},{"key":"1288_CR44","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nri1591","volume":"5","author":"PL Schwartzberg","year":"2005","unstructured":"Schwartzberg PL, Finkelstein LD, Readinger JA. TEC-family kinases: regulators of T-helper-cell differentiation. Nat Rev Immunol. 2005;5:284\u201395.","journal-title":"Nat Rev Immunol"},{"key":"1288_CR45","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/imm.13416","volume":"164","author":"C McDonald","year":"2021","unstructured":"McDonald C, Xanthopoulos C, Kostareli E. The role of Bruton\u2019s tyrosine kinase in the immune system and disease. Immunology. 2021;164:722\u201336.","journal-title":"Immunology"},{"key":"1288_CR46","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1084\/jem.192.11.1611","volume":"192","author":"W Ellmeier","year":"2000","unstructured":"Ellmeier W, Jung S, Sunshine MJ, Hatam F, Xu Y, Baltimore D, et al. Severe B cell deficiency in mice lacking the Tec kinase family members Tec and Btk. J Exp Med. 2000;192:1611\u201324.","journal-title":"J Exp Med"},{"key":"1288_CR47","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.4049\/jimmunol.1601285","volume":"198","author":"MJW de Bruijn","year":"2017","unstructured":"de Bruijn MJW, Rip J, van der Ploeg EK, van Greuningen LW, Ta VTB, Kil LP, et al. Distinct and overlapping functions of TEC kinase and BTK in B cell receptor signaling. J Immunol. 2017;198:3058\u201368.","journal-title":"J Immunol"},{"key":"1288_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.662223","volume":"12","author":"GE Ringheim","year":"2021","unstructured":"Ringheim GE, Wampole M, Oberoi K. Bruton\u2019s tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK iInhibitor specificity profiles and recent clinical trial successes and failures. Front Immunol. 2021;12:662223.","journal-title":"Front Immunol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01288-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01288-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01288-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T11:36:52Z","timestamp":1724326612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-024-01288-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1288"],"URL":"https:\/\/doi.org\/10.1038\/s41401-024-01288-7","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"assertion":[{"value":"20 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest. All the research data in this manuscript were completed by Xu\u2019s group and supported by the listed funding. Authors SWZ and YXY were employed by Jiangsu Simcere Pharmaceutical Co., Ltd. and were involved in the discussion of the content of the paper. However, they declare no conflict of interest on the publication of the research paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}